Skip to search formSkip to main contentSkip to account menu

OBP-801

Known as: HDAC Inhibitor OBP-801, Histone Deacetylase Inhibitor OBP-801 
An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of… 
National Institutes of Health

Related topics

Related topics

1 relation
YM753

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells.
PURPOSE Myxofibrosarcoma is characterized by a high rate of recurrence after surgery. Since myxofibrosarcoma is refractory to… 
2019
2019
Comprehensive Exploration to Identify Predictive DNA Markers of ΔNp63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma
BackgroundOBP-801 is a novel histone deacetylase inhibitor being developed as an anticancer drug. In this study, we explored… 
2018
2018
OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells
Subsequent to the publication of the above article, the authors have realized that errors were introduced into Fig. 4 at the… 
2018
2018
Abstract 5847: A histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth with apoptosis in triple-negative breast cancer cells
Purpose: Triple negative breast cancer (TNBC) is the most aggressive subtype in breast cancer. Eribulin is one of the well… 
2016
2016
A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
The prognosis of muscle-invasive bladder cancer with metastasis is poor. There have been no therapeutic improvements for many… 
2016
2016
A Histone Deacetylase Inhibitor , OBP-801 , and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR 5-Dependent Pathway in Bladder Cancer Cells
The prognosis of muscle-invasive bladder cancer with metastasis is poor. There have been no therapeutic improvements for many… 
2016
2016
Abstract 1110: Inhibition of histone deacetylase induces miR-320-mediated androgen receptor suppression in prostate cancer
Targeting androgen receptor (AR) by pharmacological intervention is one of the effective approaches for treatment of malignant… 
2013
2013
Abstract 672: Histone deacetylase inhibition has potential to suppresse growth of androgen dependent and independent prostate cancerin vitroandin vivo.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Histone acetylation plays an important role in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)